By Chris Wack
Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500.
The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors, showing tumor shrinkage in 50% of heavily pretreated participants, with no significant adverse events.
VIR-5818 is being tested alone and with pembrolizumab across various cancers, including breast and colorectal cancer.
The San Francisco company said VIR-5500, for metastatic castration-resistant prostate cancer, has shown PSA reductions in all participants.
Both drugs exhibit favorable safety profiles with no dose-limiting cytokine release syndrome or toxicities, suggesting effective tumor-specific activation due to the PRO-XTEN masking technology. Both studies continue dose escalation, with no maximum tolerated dose yet determined, and are exploring less frequent dosing due to prolonged drug half-life.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 08, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。